Striatal dopamine release in schizophrenia comorbid with substance dependence
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Dopamine (DA) has a role in the pathophysiology of schizophrenia and addiction. Imaging studies have indicated that striatal DA release is increased in schizophrenia, predominantly in the precommissural caudate (preDCA), and blunted in addiction, mostly in the ventral striatum (VST). Therefore, we aimed to measure striatal DA release in patients with comorbid schizophrenia and substance dependence. We used [11C]raclopride positron emission tomography and an amphetamine challenge to measure baseline DA D2-receptor availability (BPND) and its percent change post-amphetamine (ΔBPND, to index amphetamine-induced DA release) in striatal subregions in 11 unmedicated, drug-free patients with both schizophrenia and substance dependence, and 15 healthy controls. There were no significant group differences in baseline BPND. Linear mixed modeling using ΔBPND as the dependent variable and striatal region of interest as a repeated measure indicated a significant main effect of diagnosis, F(1, 24)=8.38, P=0.008, with significantly smaller ΔBPND in patients in all striatal subregions (all P⩽0.04) except VST. Among patients, change in positive symptoms after amphetamine was significantly associated with ΔBPND in the preDCA (rs=0.69, P=0.03) and VST (rs=0.64, P=0.05). In conclusion, patients with comorbid schizophrenia and substance dependence showed significant blunting of striatal DA release, in contrast to what has been found in schizophrenia without substance dependence. Despite this blunting, DA release was associated with the transient amphetamine-induced positive-symptom change, as observed in schizophrenia. This is the first description of a group of patients with schizophrenia who display low presynaptic DA release, yet show a psychotic reaction to increases in D2 stimulation, suggesting abnormal postsynaptic D2 function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Self-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Self-citationImaging dopamine's role in drug abuse and addiction
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.022 · Cited by 988
Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R., Chen, A. D., Dewey, S. L., & Pappas, N. (1997) · Nature · doi:10.1038/386830a0 · Cited by 854
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Martinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D.-R., Huang, Y., Cooper, T., Kegeles, L., Zarahn, E., Abi-Dargham, A., et al. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000048520.34839.1a · Cited by 569
Self-citationIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Self-citationMawlawi, O., Martinez, D., Slifstein, M., Broft, A., Chatterjee, R., Hwang, D.-R., Huang, Y., Simpson, N., Ngo, K., Van Heertum, R., et al. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200109000-00002 · Cited by 525
Self-citationVolkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Jayne, M., Ma, Y., Pradhan, K., & Wong, C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3371-07.2007 · Cited by 494
Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum
Martinez, D., Gil, R., Slifstein, M., Hwang, D.-R., Huang, Y., Perez, A., Kegeles, L., Talbot, P., Evans, S., Krystal, J., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.044 · Cited by 445
Self-citationMartinez, D., Narendran, R., Foltin, R. W., Slifstein, M., Hwang, D.-R., Broft, A., Huang, Y., Cooper, T. B., Fischman, M. W., Kleber, H. D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.4.622 · Cited by 351
Self-citationSwartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Canive, J. M., Miller, D. D., Reimherr, F., McGee, M., Khan, A., et al. (2006) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000202575.79453.6e · Cited by 146
Research works printed but not linked: 28
- Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761–767. · DOI · Paper page
- Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R . Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46: 56–72. · DOI · Paper page
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006; 57: 1110–1116. · DOI
- Swendsen J, Ben-Zeev D, Granholm E . Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry 2011; 168: 202–209. · DOI · Paper page
- Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999; 174: 150–153. · DOI · Paper page
- Van Mastrigt S, Addington J, Addington D . Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69–72. · DOI · Paper page
- Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190: 515–520. · DOI · Paper page
- Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141–148. · DOI · Paper page
- Verdoux H, Liraud F, Gonzales B, Assens F, Abalan F, van Os J . Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatr Scand 1999; 100: 389–395. · DOI · Paper page
- Schiffer B, Muller BW, Scherbaum N, Forsting M, Wiltfang J, Leygraf N et al. Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain 2010; 133: 3093–3103. · DOI
- Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB et al. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci 2010; 35: 95–104. · doi:10.1503/jpn.090049 · Paper page
- Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan EV . Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch Gen Psychiatry 2003; 60: 245–252. · DOI · Paper page
- Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P . Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci 2009; 259: 28–36. · DOI
- Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R . Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry 2006; 163: 689–696. · DOI · Paper page
- Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH genetics initiative. Arch Gen Psychiatry 1994; 51: 849–859. · DOI · Paper page
- First MB, Spitzer RL, Gibbon M, Williams JBW . Structured Clinical Interview for DSM-IV Axis I Disorders - Non-Patient Edition. New York Biometrics Research: New York State Psychiatric Institute, New York, NY, USA, 1996.
- Hollingshead AB . Four Factor Index of Social Status, Working paper Connecticut, 1975 (Unpublished Working Paper, Department of Sociology, Yale University, New Haven, CT, USA).
- Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276. · DOI · Paper page
- Watabe H, Endres CJ, Breier A, Schmall B, Eckelman WC, Carson RE . Measurement of dopamine release with continuous infusion of [11C]raclopride: Optimization and signal-to-noise considerations. J Nucl Med 2000; 41: 522–530.
- van Kammen DP, Murphy DL . Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 1975; 44: 215–224. · DOI · Paper page
- Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36: 1182–1190.
- Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 2009; 166: 1170–1177. · DOI · Paper page
- Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al. Dopamine release in chronic cannabis users: A [(11)C]raclopride positron emission tomography study. Biol Psychiatry 2012; 71: 677–683. · DOI · Paper page
- Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 2008; 165: 507–514. · DOI · Paper page
- Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA . Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse 2009; 63: 681–689. · DOI · Paper page
- Michaelides M, Thanos PK, Kim R, Cho J, Ananth M, Wang GJ et al. PET imaging predicts future body weight and cocaine preference. Neuroimage 2012; 59: 1508–1513. · DOI
- Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies. Arch Gen Psychiatry 2012: doi:10.1001/archgenpsychiatry.2012.1169. · DOI · Paper page
- Schubert KO, Focking M, Prehn JH, Cotter DR . Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 2011; 0: 1–13.
Cited by
McCutcheon, R. A., Reis Marques, T., & Howes, O. D. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.3360 · Cited by 1,481
Schizophrenia: an integrated sociodevelopmental-cognitive model
Howes, O. D., & Murray, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62036-x · Cited by 864
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“Decreased amphetamine-induced dopamine release has been demonstrated in dual-diagnosis patients compared with healthy controls (Thompson et al., 2013).”
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 601
The effects of Δ9-tetrahydrocannabinol on the dopamine system
Bloomfield, M. A. P., Ashok, A. H., Volkow, N. D., & Howes, O. D. (2016) · Nature · doi:10.1038/nature20153 · Cited by 373
Metadata
- Authors
- Thompson, J. L., Urban, N., Slifstein, M., Xu, X., Kegeles, L. S., Girgis, R. R., Beckerman, Y., Harkavy-Friedman, J. M., Gil, R., & Abi-Dargham, A.
- Venue
- Molecular Psychiatry
- Published
- 2012-08-07
- Volume
- 18
- Issue
- 8
- Pages
- 909-915
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2003077005
- Cited by
- 106
- References
- 15
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.